Headlines about PhaseRx (NASDAQ:PZRX) have trended somewhat positive on Monday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PhaseRx earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the company an impact score of 48.1464258133257 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of PhaseRx (PZRX) traded down 1.22% during trading on Monday, hitting $0.81. 27,379 shares of the stock were exchanged. The firm’s market capitalization is $9.47 million. The firm has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.68. PhaseRx has a 52 week low of $0.01 and a 52 week high of $3.30.

PhaseRx (NASDAQ:PZRX) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.09). Analysts forecast that PhaseRx will post ($1.46) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact PhaseRx (PZRX) Share Price” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-phaserx-pzrx-share-price/1603576.html.

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Insider Buying and Selling by Quarter for PhaseRx (NASDAQ:PZRX)

Receive News & Ratings for PhaseRx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.